PPD

PharmaTimes clinical research awards to be presented Feb. 26

Thursday, February 12, 2015 03:33 PM

The 2015’s PharmaTimes Clinical Researcher of the Year—The Americas awards will be presented Feb. 26 in North Carolina.

More... »


PPD expands GMP laboratory in Ireland

Wednesday, January 21, 2015 12:59 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., has expanded its good manufacturing practices (GMP) operations in Athlone, Ireland, by adding a new, state-of-the-art laboratory for cell-based assays to its existing portfolio of services at the facility. The new lab provides GMP bioassay testing with dedicated areas to support cell culture activities with multiple assay endpoint expertise.

More... »


X-Chem collaborates with Janssen and Johnson & Johnson Innovation

Monday, January 12, 2015 02:40 PM

X-Chem, a privately held biotechnology company based in Waltham, Mass., applying its drug discovery platform to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases.

More... »

PPD, SNBL form Japanese clinical development joint venture

Monday, January 5, 2015 12:33 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and Japan-based Shin Nippon Biomedical Laboratories (SNBL) have formed a joint venture to provide a full range of clinical development services in Japan, including phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.

More... »

PPD, ERT partner to enhance drug development

Wednesday, December 17, 2014 12:28 PM

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and ERT, a Philadelphia, Pa.-based provider of patient safety and efficacy data collection solutions, have partnered to facilitate delivery of ERT’s comprehensive solutions for patient safety and efficacy endpoint data collection to help biopharmaceutical clients conduct clinical trials in a more efficient and cost-effective manner.

More... »

PPD’s Randy Anderson named Health Care Hero for diabetes research

Thursday, November 20, 2014 12:49 PM

Randy Anderson, Ph.D., vice president of global product development and therapeutic area leader for metabolics at global CRO Pharmaceutical Product Development (PPD), was named a 2014 Health Care Hero. The annual awards honor members of the greater Wilmington medical community for their engagement on critical health issues.

More... »

PRA Health Sciences becomes latest big CRO to launch IPO

Thursday, November 13, 2014 03:38 PM

PRA Health Sciences launched its initial public offering this morning, raising $306 million from the sale of nearly 17 million shares at $18 per share—below plans it announced in September to raise up to $375 million.

More... »

Medidata, PPD partner to offer new approach to risk-based monitoring

Monday, November 10, 2014 12:22 PM

Medidata, a New York-based global provider of cloud-based solutions for clinical research in life sciences, and Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based global CRO, are expanding their partnership to provide the life science industry with a more comprehensive approach to risk-based monitoring (RBM)—aimed at conducting drug development more intelligently, more quickly and more cost-effectively.

More... »

PPD acquires X-Chem

Tuesday, October 7, 2014 10:30 AM

Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based CRO, has exercised its option to acquire the remaining minority ownership interest of X-Chem. X-Chem, a biotechnology company based in Waltham, Mass., will continue to operate as a biotechnology company with its entire existing staff, including its management team led by CEO and founder Richard W. Wagner, Ph.D., along with executive management team members Diala Ezzeddine, Ph.D., chief business officer; Matthew Clark, Ph.D., sr. vice president of research; and Lee Babiss as chairman of the board.

More... »

The CenterWatch Monthly, October 2014

Wednesday, October 1, 2014 06:00 AM

CROs driving changes in patient recruitment

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs